NovoCure Announces Leadership Changes

TL;DR

Doyle out as Exec Chair, Marcus steps in. New CFO appointed. Big leadership shakeup at NVCR.

AI Summary

NovoCure Ltd. announced on August 30, 2024, a significant leadership transition. Dr. William F. Doyle will step down as Executive Chairman and Director, effective September 3, 2024. He will be succeeded by Mr. Joel S. Marcus, who will transition from his role as Chairman of the Board to Executive Chairman. The company also announced the appointment of Ms. Ashley L. Rynd as Chief Financial Officer, effective September 3, 2024.

Why It Matters

This filing signals a shift in leadership at NovoCure, with the departure of a key executive and the appointment of a new CFO, which could impact the company's strategic direction and financial management.

Risk Assessment

Risk Level: medium — Leadership changes can introduce uncertainty regarding strategy and execution, potentially impacting investor confidence and company performance.

Key Players & Entities

• NovoCure Ltd. (company) — Registrant
• Dr. William F. Doyle (person) — Departing Executive Chairman
• Mr. Joel S. Marcus (person) — Incoming Executive Chairman
• Ms. Ashley L. Rynd (person) — Appointed Chief Financial Officer
• August 30, 2024 (date) — Date of Report
• September 3, 2024 (date) — Effective Date of Changes

FAQ

Key Financial Figures

• $615,000 — agreement, Mr. Groenhuysen will receive $615,000 per year through September 30, 2025 a
• $120,000 — r year through September 30, 2025 and $120,000 per year through the End Date (the "Bas

Filing Documents

• nvcr-20240830.htm (8-K) — 34KB
• senioradvisoremploymentagr.htm (EX-10.1) — 116KB
• specialreportprsept2024.htm (EX-99.1) — 13KB
• 0001645113-24-000029.txt ( ) — 318KB
• nvcr-20240830.xsd (EX-101.SCH) — 2KB
• nvcr-20240830_lab.xml (EX-101.LAB) — 21KB
• nvcr-20240830_pre.xml (EX-101.PRE) — 12KB
• nvcr-20240830_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 3, 2024, the Company issued a press release announcing the resignations of Asaf Danziger as Chief Executive Officer and Wilhelmus Groenhuysen as Chief Operating Officer, and the appointment of Ashley Cordova as Chief Executive Officer, in addition to other management changes. A copy of the press release is attached to this report as Exhibit 99.1.

01 Other Events

Item 8.01 Other Events. In connection with Mr. Groenhuysen's acceptance of his new position as Senior Advisor, Mr. Groenhuysen has entered into a new employment agreement with a subsidiary of the Company (the "Groenhuysen Employment Agreement"), effective October 1, 2024, to replace his existing employment agreement, dated as of September 1, 2020.Under the Groenhuysen Employment Agreement, Mr. Groenhuysen's employment is "at-will" and may be terminated by either Mr. Groenhuysen or us at any time, subject to our obligation to provide severance in certain instances as discussed below. Mr. Groenhuysen's employment agreement terminates at the close of business on April 30, 2026 (the "End Date"), unless sooner terminated in accordance with his agreement. During the term of his agreement, Mr. Groenhuysen will receive $615,000 per year through September 30, 2025 and $120,000 per year through the End Date (the "Base Salary"), subject to adjustment by the Company's Compensation Committee of the Board of Directors if Mr. Groenhuysen is a full-time employee of another company after January 1, 2025. Upon termination of Mr. Groenhuysen's employment by the Company without "cause" (but for reasons other than death or "disability") or resignation by Mr. Groenhuysen for "good reason" (each a "Qualifying Termination") within 12 months following a change in control, and subject to Mr. Groenhuysen's execution without revocation of a release of claims, Mr. Groenhuysen will be eligible to receive an amount equal to the sum of 1.5 times his Base Salary times a fraction equal to the number of days remaining from the date of the Qualifying Termination through the End Date divided by the total number of days of the effective date through the End Date, and to the extent he timely elects COBRA continuation coverage and pays the full monthly premiums, a monthly amount equal to the full monthly premium for COBRA continuation coverage for the level of coverage in effect for Mr.Groenhuysen and

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Employment Agreement between Wilhelmus Groenhuysen and Novocure USA LLC effective as of October 1, 2024 99.1 Press Release of NovoCure Limited, dated September 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: September 3, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR